Cerus Enters Into Purchase Agreement with The Community Blood Center

Medical Device Investing

Cerus Corporation (NASDAQ: CERS) reported that it has signed a purchase agreement for the INTERCEPT Blood System for platelets and plasma with The Community Blood Center (CBC).

Cerus Corporation (NASDAQ: CERS) reported that it has signed a purchase agreement for the INTERCEPT Blood System for platelets and plasma with The Community Blood Center (CBC).
According to the press release:

CBC delivers blood components to 17 hospitals in the state of Wisconsin and one in the state of Michigan, distributing approximately 13,500 platelet and 11,500 plasma units annually.
“Providing safe and reliable blood components to the hospitals and patients in our community is of top priority for us,” said John Hagins, CBC’s President and Chief Executive Officer. “INTERCEPT will allow us to take a proactive approach against transfusion-transmitted infections, making a partnership with Cerus an obvious choice.”
“The blood components provided by CBC are vital to the community hospitals they serve,” commented William “Obi” Greenman, Cerus’ President and Chief Executive Officer. “We are pleased that they have chosen to implement the INTERCEPT Blood System to ensure that the platelet and plasma components reaching their patients are of the highest safety standard available.”

Click here to read the full press release.

 

The Conversation (0)
×